The carbon footprint of pharmaceuticals for diabetes and cardiovascular diseases

Study type

• Study topic:
  Human medicinal product

  Other
• Study topic, other:
  Carbon footprint
• Study type:
  Non-interventional study
• Scope of the study:
  Scoping review (including literature review)
• Data collection methods:
  No individual level data collected for the purpose of the study

Non-interventional study

• Non-interventional study design:
  Other
• Non-interventional study design, other:
  Scoping review

Study drug and medical condition

• Anatomical Therapeutic Chemical (ATC) code:
  (A10) DRUGS USED IN DIABETES

  DRUGS USED IN DIABETES

  (C) CARDIOVASCULAR SYSTEM

  CARDIOVASCULAR SYSTEM
• Additional medical condition(s):
  ATC group A10 and C (excluding C05A)

Study design details

• Study design:
  Scoping review with search in PubMed, Scopus, Embase and Web Of Science.
• Main study objective:
  Objective: This scoping review aims to gather published knowledge about the carbon footprint of pharmaceuticals for diabetes (ATC A) and cardiovascular disease (ATC C, excluding C05A) reported in peer reviewed publications.
• Setting:
  Inclusion;  Language: English; ;  Peer reviewed original article. ; ;  A carbon footprint reported on a pharmaceutical.; ;  Pharmaceutical from the pharmacological group ATC A10 (antidiabetic pharmaceutical) or ATC C (cardiovascular pharmaceutical) excluding ATC C05A (pharmaceuticals for hemorrhiods and anal fissures). ; ;  Reporting of the absolute number of the carbon footprint e.g. in a unit measurement of CO2-equivalent.; ;  Articles published before June 1st, 2025. ; ; Exclusion;  Carbon footprint only on packaging or transportation of the pharmaceutical.; ;  Carbon footprint only reported in percentage without information that enable absolute calculation of carbon footprint.